| Ernest J Oddono Jr, MD | |
|
131 Saundersville Rd, Suite 180, Hendersonville, TN 37075-8903 | |
| (615) 824-3737 | |
| (855) 540-4722 |
| Full Name | Ernest J Oddono Jr |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 34 Years |
| Location | 131 Saundersville Rd, Hendersonville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780634691 | NPI | - | NPPES |
| 8963680 | Medicaid | NC | |
| 5714541 | Medicaid | VA | |
| 63680 | Other | NC | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 9400116 (North Carolina) | Secondary |
| 208VP0000X | Pain Medicine - Pain Medicine | 94001169400116 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Moses H. Cone Memorial Hospital, The | Greensboro, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesiology Consultants Of North Carolina Pllc | 7810256971 | 24 |
News Archive
The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.
As governments, industry and public interest groups from across the globe prepare to meet next week to discuss endocrine-disrupting chemicals and other international chemical safety issues, the Endocrine Society and IPEN released a new guide documenting the threat endocrine-disrupting chemicals (EDCs) pose to human health.
Research from Melbourne's Howard Florey Institute and the Austin Hospital has resulted in a drug to treat kidney failure during septic shock, which will be trialled at the Austin Hospital from mid-2007.
The aim of personalizing cancer treatments by targeting genomic mutations in the cancer has seen rapid advances in recent years. However, many of these targeted cancer therapies have been more frequently identified for adult patients. Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.
› Verified 8 days ago
| Entity Name | Gate City Anesthesia, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225135361 PECOS PAC ID: 8820089329 Enrollment ID: O20040522000305 |
News Archive
The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.
As governments, industry and public interest groups from across the globe prepare to meet next week to discuss endocrine-disrupting chemicals and other international chemical safety issues, the Endocrine Society and IPEN released a new guide documenting the threat endocrine-disrupting chemicals (EDCs) pose to human health.
Research from Melbourne's Howard Florey Institute and the Austin Hospital has resulted in a drug to treat kidney failure during septic shock, which will be trialled at the Austin Hospital from mid-2007.
The aim of personalizing cancer treatments by targeting genomic mutations in the cancer has seen rapid advances in recent years. However, many of these targeted cancer therapies have been more frequently identified for adult patients. Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.
› Verified 8 days ago
| Entity Name | Anesthesiology Consultants Of North Carolina Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811409568 PECOS PAC ID: 7810256971 Enrollment ID: O20180117001856 |
News Archive
The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.
As governments, industry and public interest groups from across the globe prepare to meet next week to discuss endocrine-disrupting chemicals and other international chemical safety issues, the Endocrine Society and IPEN released a new guide documenting the threat endocrine-disrupting chemicals (EDCs) pose to human health.
Research from Melbourne's Howard Florey Institute and the Austin Hospital has resulted in a drug to treat kidney failure during septic shock, which will be trialled at the Austin Hospital from mid-2007.
The aim of personalizing cancer treatments by targeting genomic mutations in the cancer has seen rapid advances in recent years. However, many of these targeted cancer therapies have been more frequently identified for adult patients. Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ernest J Oddono Jr, MD 131 Saundersville Rd, Suite 180, Hendersonville, TN 37075-8903 Ph: (615) 824-3737 | Ernest J Oddono Jr, MD 131 Saundersville Rd, Suite 180, Hendersonville, TN 37075-8903 Ph: (615) 824-3737 |
News Archive
The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.
As governments, industry and public interest groups from across the globe prepare to meet next week to discuss endocrine-disrupting chemicals and other international chemical safety issues, the Endocrine Society and IPEN released a new guide documenting the threat endocrine-disrupting chemicals (EDCs) pose to human health.
Research from Melbourne's Howard Florey Institute and the Austin Hospital has resulted in a drug to treat kidney failure during septic shock, which will be trialled at the Austin Hospital from mid-2007.
The aim of personalizing cancer treatments by targeting genomic mutations in the cancer has seen rapid advances in recent years. However, many of these targeted cancer therapies have been more frequently identified for adult patients. Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.
› Verified 8 days ago
Dr. Brad P Wilson, D.O. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 353 New Shackle Island Rd Ste 148c, Hendersonville, TN 37075 Phone: 615-972-1100 Fax: 615-537-4950 |